Tobramycin
Who holds supplier records for Tobramycin? 3 organisations hold a current record for Tobramycin: an active US FDA Type II Drug Master File or a CEP. A further 4 organisations have only historical (inactive) DMF filings. 3 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (1) and Netherlands (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Tobramycin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/tobramycin
Reading the evidence
- 3 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Tobramycin expires 4 Nov 2030. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (3)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Tobramycin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Chongqing Daxin Pharmaceutical Co., Ltd.ChinaCEPActive DMF 13774 · latest filing Sept 1998
- LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDCEP Company GMP cert on recordActive DMF 35042 · latest filing Aug 2020
- TAPI NL BVNetherlandsCEPActive DMF 13713 · latest filing Sept 1998
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (3)
Certificates of Suitability on the EDQM register for Tobramycin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 7 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO., LTD. Fuzhou | CN | CEP 2024-023 - Rev 02 Tobramycin, Spray-dried, amorphous | Jun 2026 | Inspected Apr 2025 Germany |
| CHONGQING DAXIN PHARMACEUTICAL CO., LTD. Shuitu Town | CN | CEP 2019-036 - Rev 02 Tobramycin, EHS Optimized Process | Jan 2026 | — |
| TAPI NL B.V. Amsterdam | NL | CEP 1997-046 - Rev 07 Tobramycin | Feb 2025 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (4)
Organisations whose Type II DMFs for Tobramycin are no longer active. These show a past filing, not current supply.
Show all 4 historical records
- China · Inactive DMF 20724 · filed Jul 2007
- PHARMACHIM ECONOMIC CORPInactive DMF 13739, 13740 · filed Sept 1998
- China · Inactive DMF 13770 · filed Sept 1998
- GUANGDONG QINGYUAN NEW NORTH RIVER PHARMACEUTICAL CO LTDInactive DMF 12128 · filed Sept 1996
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (36 listed products contain Tobramycin). The latest listed patent expires 4 Nov 2030. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Tobramycin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1747).
Chemical identity
- IUPAC name
- (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
- Canonical SMILES
- C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
- InChIKey
- NLVFBUXFDBBNBW-PBSUHMDJSA-N
- Synonyms
- 47663, Aktob, Bethkis, Bramitob, Kitabis pak, Nebcin, Nebicin, Nebramycin factor 6, Nebramycin vi, Nebris, NSC-180514, Tobi
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Aminoglycoside Antibacterial
- Chemical structure
- Aminoglycosides
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Tobramycin?
3 organisations hold an active US FDA Type II Drug Master File or a CEP for Tobramycin: Chongqing Daxin Pharmaceutical Co., Ltd. (China), LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Tobramycin Drug Master Files are active?
Chongqing Daxin Pharmaceutical Co., Ltd. (DMF 13774), LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTD (DMF 35042) and TAPI NL BV (DMF 13713). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Tobramycin records mean?
4 organisations have only inactive Type II DMFs for Tobramycin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Tobramycin have a European Certificate of Suitability?
Yes. 3 organisations hold a valid CEP for Tobramycin on the EDQM register, including LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO., LTD. Fuzhou (CN), CHONGQING DAXIN PHARMACEUTICAL CO., LTD. Shuitu Town (CN) and TAPI NL B.V. Amsterdam (NL). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Tobramycin?
Yes. The latest patent listed for an approved US product containing Tobramycin expires 4 Nov 2030, across 36 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Tobramycin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Tobramycin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.